GeneDx Holdings (NasdaqGS:WGS) reported new research showing exome and genome sequencing informed clinical management in over 60% of tested patients. The real-world analysis covered more than 300,000 individuals who received GeneDx genomic testing across a broad clinical setting. GeneDx plans to present the findings at the NSGC 2026 Annual Conference, highlighting the clinical impact of its sequencing platform. The large real-world study on actionable exome and genome results is only one...
GeneDx Holdings (WGS) is back in focus after releasing third quarter 2026 results, showing higher revenue alongside a wider net loss and updated guidance that keeps full year revenue expectations unchanged. The latest earnings update has landed in a tough tape for GeneDx Holdings. The share price has fallen about 59% year to date and the 1 year total shareholder return is down roughly 61%. The 3 year total shareholder return is extremely high, pointing to strong earlier gains but fading...
GeneDx Holdings Corp (WGS) delivered 72% adjusted gross margin and $8.6 million in adjusted net income for Q3 2026, while guiding Q4 revenue to at least $135 million despite PAMA headwinds.
GeneDx is nearing sustained profitability after a Q3 revenue beat. Valuation is slightly above the sector median. See here for an analysis of WGS stock.
Investing.com -- GeneDx Holdings Corp (NASDAQ:WGS) reported third quarter results that met revenue expectations but cut its full-year growth targets, sending shares down 10.2% in after-hours trading Monday.
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +300.00% and +0.82%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals recently announced a collaboration with GeneDx Holdings to provide fully sponsored ExomeDx testing and genetic counseling across cholestasis, early-onset cataracts, and PBD-ZSD programs, with no insurance claims filed for eligible patients. This sponsored access could deepen GeneDx Holdings’ reach in rare disease diagnostics by increasing test volumes, clinician touchpoints, and data accrual without adding direct cost for patients. We will now examine how GeneDx...
GAITHERSBURG, Md., September 09, 2026--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md., September 01, 2026--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity
GAITHERSBURG, Md., August 24, 2026--GeneDx and Seattle Children’s show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
This is the newest page. Registered accounts read further back.